RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis

被引：0
|
作者：
Savira, Feby [1 ,2 ]
Kompa, Andrew R. [2 ,3 ]
Edgley, Amanda J. [3 ]
Jucker, Beat M. [4 ]
Willette, Robert N. [4 ]
Kelly, Darren J. [3 ]
Wang, Bing H. [1 ,2 ]
机构：
[1] Baker Heart & Diabet Res Inst, Biomarker Discovery Lab, Melbourne, Vic, Australia
[2] Monash Univ, Monash Ctr Cardiovasc Res & Educ Therapeut, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[3] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia
[4] GlaxoSmithKline, Heart Failure Discovery Performance Unit, King Of Prussia, PA USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2021年 / 326卷
基金：
英国医学研究理事会;
关键词：
INDOXYL SULFATE; CELLS;
D O I：
10.1016/j.ijcard.2020.10.035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：156 / 156
页数：1
相关论文
共 50 条
  • [1] Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis
    Wei, Wen-Ying
    Lian, Zhe-Xun
    Ji, Yang
    Zhang, Ning
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 323 : 205 - 205
  • [2] Inhibition of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome
    Savira, F.
    Wang, B. H.
    Edgley, A. J.
    Krum, H.
    Kelly, D. J.
    Kompa, A. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 317 - 317
  • [3] Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome
    Savira, Feby
    Wang, Bing H.
    Edgley, Amanda J.
    Jucker, Beat M.
    Willette, Robert N.
    Krum, Henry
    Kelly, Darren J.
    Kompa, Andrew R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 310 : 128 - 136
  • [4] RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome
    Savira, Feby
    Edgley, Amanda J.
    Jucker, Beat M.
    Willette, Robert N.
    Krum, Henry
    Kelly, Darren J.
    Kompa, Andrew R.
    Wang, Bing H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 323 : 260 - 260
  • [5] Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome
    Savira, Feby
    Cao, Longxing
    Wang, Ian
    Yang, Wendi
    Huang, Kevin
    Hua, Yue
    Jucker, Beat M.
    Willette, Robert N.
    Huang, Li
    Krum, Henry
    Li, Zhiliang
    Fu, Tang
    Wang, Bing Hui
    PLOS ONE, 2017, 12 (11):
  • [6] Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome
    Pan, Jie
    Wang, Lin
    Sun, Ying
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 320 : 139 - 139
  • [7] Cardiac-specific activation of apoptosis signal-regulating kinase 1 leads to cardiac dysfunction with pathological hypertrophy
    Takeda, Toshihiro
    Otsu, Kinya
    Yamaguchi, Osamu
    Hirotani, Shinichi
    Hikoso, Shungo
    Higuchi, Yoshiharu
    Taniike, Masayuki
    Nakai, Atsuko
    Omiya, Shigemiki
    Mizote, Isamu
    Taneike, Manabu
    Oka, Takafumi
    Nishida, Kazuhiko
    Hori, Masatsugu
    CIRCULATION, 2007, 116 (16) : 18 - 18
  • [8] Important role of apoptosis signal-regulating kinase 1 in ischemia-induced angiogenesis
    Izumi, Y
    Kim-Mitsuyama, S
    Yoshiyama, M
    Omura, T
    Shiota, M
    Matsuzawa, A
    Yukimura, T
    Murohara, T
    Takeya, M
    Ichijo, H
    Yoshikawa, J
    Iwao, H
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (09) : 1877 - 1883
  • [9] The role of apoptosis signal-regulating kinase 1 in cardiomyocyte apoptosis
    Nishida, Kazuhiko
    Otsu, Kinya
    ANTIOXIDANTS & REDOX SIGNALING, 2006, 8 (9-10) : 1729 - 1736
  • [10] Apoptosis signal-regulating kinase 1 as a therapeutic target
    Kawarazaki, Yosuke
    Ichijo, Hidenori
    Naguro, Isao
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (06) : 651 - 664
12345